98%
921
2 minutes
20
Background: Spondylodiscitis requires timely diagnosis and intervention to prevent infection progression and long-term complications. While clinical experience often guides treatment decisions, the lack of strong evidence-based protocols has created a significant gap in care. To address this, Pluemer et al. developed the "Spinal Infection Treatment Evaluation" (SITE) score, which incorporates variables such as neurological symptoms, infection location, radiological findings, pain severity, and comorbidities, to support neurosurgeons in making more evidence-based therapeutic decisions.
Methods: A retrospective study was conducted on 42 patients with de novo spinal infections who underwent surgery between March 2018 and March 2023 at 2 neurosurgical centers. All patients were aged more than 18 years and had not responded to medical therapy. Key data, including patient demographics, infection sites, laboratory results (C-reactive protein, white blood cell), neurological status, and magnetic resonance imaging findings were examined. Functional outcomes were measured using the visual analog scale and Core Outcome Measures Index. The SITE score was applied retrospectively to assess its relevance to treatment decisions.
Results: Staphylococcus aureus was the most frequent pathogen (47.6%), and 76% of patients presented with neck or back pain. The SITE score accurately predicted surgical intervention in 98% of cases. Pain levels significantly decreased, with the preoperative visual analog scale score of 6.59 reducing to 2.17 6 months post-treatment. Functional improvements were also evident, with Core Outcome Measures Index scores dropping from 5.4 preoperatively to 1.9 at 6 months.
Conclusions: The SITE score proves to be a promising tool for evaluating the severity of de novo spinal infections and guiding treatment strategies. By integrating multiple clinical factors, it offers an objective framework that can enhance patient outcomes. However, further validation across different clinical settings is needed to solidify its utility in evidence-based care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2025.123994 | DOI Listing |
World J Surg
September 2025
Research Laboratory "Developmental and Induced Diseases" (LR19ES12), Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia.
This study identified cardiac comorbidities, prematurity, low 5-min Apgar score, and prolonged postoperative intubation as independent risk factors for NIs following surgical repair of EA. We believe that these results would be of great value in clinical practice. They provide a valuable framework for the early identification of high-risk neonates, who would be targets for enhanced infection surveillance, appropriate perioperative strategies, and reinforced hygiene protocols.
View Article and Find Full Text PDFVet Anaesth Analg
June 2025
School of Veterinary Science, University of Queensland, Brisbane, Australia. Electronic address:
Objective: To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization.
Study Design: Blinded, randomized study.
Animals: A group of 26 university-owned research horses.
Respir Med Res
August 2025
Cystic Fibrosis Center Service de Pneumologie Pôle des Voies Respiratoires, Hôpital Larrey CHU de Toulouse, Toulouse, France.
Background: Little is known about the characteristics of adults with bronchiectasis in France.
Methods: A descriptive cross-sectional study was conducted to describe the characteristics of adults (≥18 years) with clinically-significant bronchiectasis, diagnosed on a combination of respiratory symptoms and CT scan findings, and followed in 18 participating centers. Data on, etiology, lung function, symptoms, microbiology, treatments and quality of life were collected.
Brain
September 2025
Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, 18016 Granada, Spain.
Primary coenzyme Q (CoQ) deficiency is a mitochondrial disorder with variable clinical presentation and limited response to standard CoQ10 supplementation. Recent studies suggest that 4-hydroxybenzoic acid (4-HBA), a biosynthetic precursor of CoQ, may serve as a substrate enhancement treatment in cases caused by pathogenic variants in COQ2, a gene encoding a key enzyme in CoQ biosynthesis. However, it remains unclear whether 4-HBA is required throughout life to maintain health, whether it offers advantages over CoQ10 treatment, and whether these findings are translatable to humans.
View Article and Find Full Text PDFJ Invasive Cardiol
September 2025
Cardiac Surgery Unit, Mediterranea Cardiocentro, Naples, Italy.
Objectives: Failure of vascular closure device (VCD) is the most common cause of access-site vascular complications in transfemoral transcatheter aortic valve implantation (TAVI). The authors sought to determine if the systematic use of arteriotomy-site ballooning with concomitant manual compression following the delivery of a plug-based VCD (MANTA, Teleflex) can optimize toggle-plug assembly apposition to the common femoral artery (CFA) wall and improve the final hemostatic efficacy.
Methods: In this prospective, observational, single-center study, 323 consecutive patients undergoing transfemoral TAVI from October 2021 to December 2024 underwent access closure with the MANTA VCD.